NeoGenomics, Inc.

Valuation Analysis

About the Company

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visu

NeoGenomics, Inc. Stock at a Glance

NeoGenomics, Inc. (NEO) is currently trading at $11.15 with a market capitalization of $1.5B. The 52-week range spans from $4.72 to $13.74; the current price is 18.9% below the yearly high. Year-over-year revenue growth stands at +11.1%.

💰 Dividend

NeoGenomics, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

9 analysts rate NeoGenomics, Inc. (NEO) on consensus: Buy. The average price target is $15.06, implying +35.03% from the current price. Analyst price targets range from $11.00 to $25.00.

NeoGenomics, Inc.: The Investment Case in Detail

NeoGenomics, Inc. (NEO) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 11.1% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Wall Street consensus sits at Buy with an average price target implying roughly 35.03% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. With a beta near 1.81, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves.

Valuation in Context

The EV/EBITDA multiple of 401.75x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

What to Watch Next

• The analyst consensus price target implies 35.03% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to above-average price swings, elevated short interest (7.67%).

Trading Data

Related Stocks in the Same Sector

Where can I buy NeoGenomics, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.